Keyphrases
Therapeutic Targeting
100%
Androgen Receptor
100%
Castration-resistant Prostate Cancer
100%
Enzalutamide
46%
ACK1
30%
Acetylation
23%
Phosphorylation
15%
DNA-binding Domain
7%
Prostate Cancer
7%
Post-translational Modification
7%
Translocated
7%
Small Molecule Inhibitors
7%
Positive Feedback Loop
7%
Post-translational
7%
Therapeutic Potential
7%
Cancer Stage
7%
Zinc Finger
7%
Recurrent Disease
7%
Therapeutic Vulnerabilities
7%
Resistance Mechanisms
7%
Androgen Receptor Antagonist
7%
Cancer Xenograft
7%
Global Transcription
7%
Receptor Translocation
7%
Oral Treatment
7%
Xenograft Tumor Growth
7%
TNK2
7%
Resilient
7%
Resistance Acquisition
7%
Chemical Proteomics
7%
Subcutaneous Treatment
7%
Androgen Receptor Splice Variant 7
7%
Castration-resistant Prostate Cancer Cells
7%
Progressive Stages
7%
Pharmacology, Toxicology and Pharmaceutical Science
Androgen Receptor
100%
Castration Resistant Prostate Cancer
100%
Enzalutamide
42%
Tumor Growth
7%
Prostate Cancer
7%
Recurrent Disease
7%
Zinc Finger Protein
7%
Cancer Staging
7%
Androgen Receptor Antagonist
7%
Biochemistry, Genetics and Molecular Biology
Androgen Receptor
100%
Enzalutamide
40%
Acetylation
20%
Transcription
13%
Enhancer Region
6%
Cancer Cell
6%
Tumor Progression
6%
Proteomics
6%
DNA-binding Domain
6%
Posttranslational Modification
6%
Receptor Antagonist
6%
Small Molecule
6%
Positive Feedback
6%
Cancer Staging
6%